206 related articles for article (PubMed ID: 23331925)
1. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
[TBL] [Abstract][Full Text] [Related]
3. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.
Chan JC; Hannan KM; Riddell K; Ng PY; Peck A; Lee RS; Hung S; Astle MV; Bywater M; Wall M; Poortinga G; Jastrzebski K; Sheppard KE; Hemmings BA; Hall MN; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Sci Signal; 2011 Aug; 4(188):ra56. PubMed ID: 21878679
[TBL] [Abstract][Full Text] [Related]
4. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
5. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
6. Signaling to the ribosome in cancer--It is more than just mTORC1.
Hannan KM; Sanij E; Hein N; Hannan RD; Pearson RB
IUBMB Life; 2011 Feb; 63(2):79-85. PubMed ID: 21360636
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.
Shortt J; Martin BP; Newbold A; Hannan KM; Devlin JR; Baker AJ; Ralli R; Cullinane C; Schmitt CA; Reimann M; Hall MN; Wall M; Hannan RD; Pearson RB; McArthur GA; Johnstone RW
Blood; 2013 Apr; 121(15):2964-74. PubMed ID: 23403624
[TBL] [Abstract][Full Text] [Related]
8. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus X protein and c-Myc cooperate in the upregulation of ribosome biogenesis and in cellular transformation.
Shukla SK; Kumar V
FEBS J; 2012 Oct; 279(20):3859-71. PubMed ID: 22889122
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
[TBL] [Abstract][Full Text] [Related]
11. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
12. The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.
Hunter JE; Butterworth JA; Zhao B; Sellier H; Campbell KJ; Thomas HD; Bacon CM; Cockell SJ; Gewurz BE; Perkins ND
Oncogene; 2016 Jun; 35(26):3476-84. PubMed ID: 26522720
[TBL] [Abstract][Full Text] [Related]
13. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
[TBL] [Abstract][Full Text] [Related]
14. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
15. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.
Adya R; Tan BK; Punn A; Chen J; Randeva HS
Cardiovasc Res; 2008 May; 78(2):356-65. PubMed ID: 18093986
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
[TBL] [Abstract][Full Text] [Related]
17. IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway.
Carey GB; Semenova E; Qi X; Keegan AD
Cell Res; 2007 Nov; 17(11):942-55. PubMed ID: 17968425
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1.
Contreras JR; Palanichamy JK; Tran TM; Fernando TR; Rodriguez-Malave NI; Goswami N; Arboleda VA; Casero D; Rao DS
Oncotarget; 2015 May; 6(13):11023-37. PubMed ID: 25906746
[TBL] [Abstract][Full Text] [Related]
19. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
Chiarini F; Del Sole M; Mongiorgi S; Gaboardi GC; Cappellini A; Mantovani I; Follo MY; McCubrey JA; Martelli AM
Leukemia; 2008 Jun; 22(6):1106-16. PubMed ID: 18385752
[TBL] [Abstract][Full Text] [Related]
20. Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells.
Domínguez-Cáceres MA; García-Martínez JM; Calcabrini A; González L; Porque PG; León J; Martín-Pérez J
Oncogene; 2004 Sep; 23(44):7378-90. PubMed ID: 15286700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
